30
Participants
Start Date
March 15, 2018
Primary Completion Date
April 11, 2024
Study Completion Date
April 11, 2024
MDR-101
Enriched CD34+ hematopoietic stem cells and defined dose of CD3+ T-cells
Upstate University Hospital, Syracuse
Thomas Jefferson University, Philadelphia
Georgetown University Medical Center, Washington D.C.
INOVA Fairfax Hospital, Fairfax
Mayo Clinic Hospital, Jacksonville
University Hospitals Cleveland Medical Center, Cleveland
University of Wisconsin School of Medicine, Madison
Mayo Clinic, Rochester
Baylor University Medical Center, Dallas
The Methodist Hospital, Houston
University of Colorado Denver, Aurora
Intermountain Transplant Center, Murray
USC, Los Angeles
Loma Linda University Medical Center, Loma Linda
Stanford University Medical Center, Stanford
Yale University, New Haven
Loyola University Medical Center, Maywood
RWJBarnabas Health, Orange
CIUSSS de l'Est- de-l'Île-de-Montréal Installation Hopital Maisonneuve-Rosemont, Montreal
Lead Sponsor
California Institute for Regenerative Medicine (CIRM)
OTHER
Medeor Therapeutics, Inc.
INDUSTRY